- Home
- CUE vs SURG Comparison
CUE vs SURG Comparison
Compare CUE & SURG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- SURG
- Stock Information
- Founded
- CUE 2014
- SURG 2006
- Country
- CUE United States
- SURG United States
- Employees
- CUE N/A
- SURG N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- SURG Advertising
- Sector
- CUE Health Care
- SURG Consumer Discretionary
- Exchange
- CUE Nasdaq
- SURG Nasdaq
- Market Cap
- CUE 58.9M
- SURG 59.4M
- IPO Year
- CUE 2018
- SURG N/A
- Fundamental
- Price
- CUE $0.65
- SURG $2.97
- Analyst Decision
- CUE Strong Buy
- SURG Strong Buy
- Analyst Count
- CUE 3
- SURG 1
- Target Price
- CUE $3.00
- SURG $8.75
- AVG Volume (30 Days)
- CUE 163.7K
- SURG 217.7K
- Earning Date
- CUE 05-12-2025
- SURG 05-13-2025
- Dividend Yield
- CUE N/A
- SURG N/A
- EPS Growth
- CUE N/A
- SURG N/A
- EPS
- CUE N/A
- SURG N/A
- Revenue
- CUE $7,991,000.00
- SURG $40,029,467.00
- Revenue This Year
- CUE N/A
- SURG $103.68
- Revenue Next Year
- CUE $25.99
- SURG $51.08
- P/E Ratio
- CUE N/A
- SURG N/A
- Revenue Growth
- CUE 13.83
- SURG N/A
- 52 Week Low
- CUE $0.45
- SURG $1.05
- 52 Week High
- CUE $1.99
- SURG $4.38
- Technical
- Relative Strength Index (RSI)
- CUE 40.82
- SURG 53.19
- Support Level
- CUE $0.61
- SURG $3.01
- Resistance Level
- CUE $0.71
- SURG $3.17
- Average True Range (ATR)
- CUE 0.06
- SURG 0.27
- MACD
- CUE -0.00
- SURG -0.03
- Stochastic Oscillator
- CUE 30.70
- SURG 51.09
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.